Latus Bio closes $97 million Series A with BioAdvance participation

  • Latus Bio, biotechnology company developing scalable AAV gene therapies for broader patient populations, closed USD 97 million Series A financing.
  • Round included USD 43 million extension led by 8VC, with BioAdvance Capital participating alongside other existing investors.
  • Proceeds earmarked to fund operations through initial clinical data for lead programs LTS-201 in Huntington’s disease, with IND submission targeted for 3Q 2026, and LTS-101 in CLN2 disease, with first-in-human investigator-initiated trial expected in 3Q 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAdvance Capital published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.